Anne A Eaton1, Mithat Gonen2, Paul Karanicolas3, William R Jarnagin4, Michael I D'Angelica4, Ronald DeMatteo4, T Peter Kingham4, Peter J Allen4. 1. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. eatona@mskcc.org. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Odette Cancer Research Program, Sunnybrook Health Sciences Center, Toronto, ON, Canada. 4. Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: A recent prospective randomized trial demonstrated that prophylactic pasireotide reduces the incidence of pancreatic complications (PC) after resection. This secondary analysis aimed to describe quality of life (QoL) before and after resection, to characterize the impact of PC on QoL, and to assess whether pasireotide improves QoL. METHODS: A randomized, double-blind, placebo-controlled trial of preoperative pasireotide in patients undergoing pancreatectomy was conducted. Participants completed the European Organization for Research and Treatment of Cancer (EORTC) C30 and PAN26 modules preoperatively and on postoperative days 14 and 60. Scores were compared using t tests. The percentage of patients with clinically important worsening (a decline ≥0.5 times the baseline standard deviation) was reported. RESULTS: All questionnaires were completed by 87 % (260/300) of the patients. No major differences were observed between the pasireotide and placebo groups. Therefore, the data were pooled for further analyses. A significant worsening of function at 14 days was detected on all the PAN26 and C30 function scales except hepatic and emotional functioning (EF), and on all the C30 symptom scales. More than 75 % of the patients experienced clinically important worsening of fatigue, pain, and role functioning. Most effects persisted at 60 days, with the 60-day EF significantly better than at baseline (p = 0.03). PC were associated with worse outcomes on most function scales. CONCLUSIONS: During the 14 days after resection, patients can be expected to have a significant decline in QoL. Many symptoms abate by 60 days, and EF improves. PC were associated with impaired QoL in several domains. Although pasireotide effectively reduced PC, its effect did not appear to translate to improved QoL in this sample of 300 patients.
RCT Entities:
BACKGROUND: A recent prospective randomized trial demonstrated that prophylactic pasireotide reduces the incidence of pancreatic complications (PC) after resection. This secondary analysis aimed to describe quality of life (QoL) before and after resection, to characterize the impact of PC on QoL, and to assess whether pasireotide improves QoL. METHODS: A randomized, double-blind, placebo-controlled trial of preoperative pasireotide in patients undergoing pancreatectomy was conducted. Participants completed the European Organization for Research and Treatment of Cancer (EORTC) C30 and PAN26 modules preoperatively and on postoperative days 14 and 60. Scores were compared using t tests. The percentage of patients with clinically important worsening (a decline ≥0.5 times the baseline standard deviation) was reported. RESULTS: All questionnaires were completed by 87 % (260/300) of the patients. No major differences were observed between the pasireotide and placebo groups. Therefore, the data were pooled for further analyses. A significant worsening of function at 14 days was detected on all the PAN26 and C30 function scales except hepatic and emotional functioning (EF), and on all the C30 symptom scales. More than 75 % of the patients experienced clinically important worsening of fatigue, pain, and role functioning. Most effects persisted at 60 days, with the 60-day EF significantly better than at baseline (p = 0.03). PC were associated with worse outcomes on most function scales. CONCLUSIONS: During the 14 days after resection, patients can be expected to have a significant decline in QoL. Many symptoms abate by 60 days, and EF improves. PC were associated with impaired QoL in several domains. Although pasireotide effectively reduced PC, its effect did not appear to translate to improved QoL in this sample of 300 patients.
Authors: D Fitzsimmons; C D Johnson; S George; S Payne; A A Sandberg; C Bassi; H G Beger; D Birk; M W Büchler; C Dervenis; L Fernandez Cruz; H Friess; A L Grahm; J Jeekel; R Laugier; D Meyer; M W Singer; T Tihanyi Journal: Eur J Cancer Date: 1999-06 Impact factor: 9.162
Authors: Shalini Moningi; Amanda J Walker; Charles C Hsu; Jennifer Barsky Reese; Jing-Ya Wang; Katherine Y Fan; Lauren M Rosati; Daniel A Laheru; Matthew J Weiss; Christopher L Wolfgang; Timothy M Pawlik; Joseph M Herman Journal: J Oncol Pract Date: 2015-01-06 Impact factor: 3.840
Authors: E J M Nieveen van Dijkum; K F D Kuhlmann; C B Terwee; H Obertop; J C J M de Haes; D J Gouma Journal: Br J Surg Date: 2005-04 Impact factor: 6.939
Authors: Stefano Crippa; Ismael Domínguez; J Ruben Rodríguez; Oswaldo Razo; Sarah P Thayer; David P Ryan; Andrew L Warshaw; Carlos Fernández-del Castillo Journal: J Gastrointest Surg Date: 2008-03-04 Impact factor: 3.452
Authors: C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt Journal: Ann Surg Date: 1995-06 Impact factor: 12.969
Authors: S Tung; N G Coburn; L E Davis; A L Mahar; S Myrehaug; H Zhao; C C Earle; A Nathens; J Hallet Journal: Br J Surg Date: 2019-11 Impact factor: 6.939
Authors: Maria Arvaniti; Nikolaos Danias; Michael Igoumenidis; Vassilios Smyrniotis; Andreas Tsounis; Pavlos Sarafis Journal: Electron Physician Date: 2018-07-25
Authors: Anastasios Katsourakis; Ioannis Vrabas; Vassilios Papanikolaou; Stylianos Apostolidis; Iosif Chatzis; George Noussios Journal: J Clin Med Res Date: 2018-12-03
Authors: Teresa Macarulla; Andrew E Hendifar; Chung-Pin Li; Michele Reni; Hanno Riess; Margaret A Tempero; Amylou C Dueck; Marc F Botteman; Chinmay G Deshpande; Eleanor J Lucas; Do-Youn Oh Journal: Pancreas Date: 2020-03 Impact factor: 3.243